Cytosorbents Corp
CytoSorbents Corporation (Nasdaq: CTSO) develops and commercializes blood purification technologies based on porous polymer beads that remove harmful substances from blood and other bodily fluids. Its cartridges connect to standard hospital blood-pumping systems, including dialysis, continuous renal replacement… From the company’s description.
Over the twelve months to Jun 30, 2026, Cytosorbents Corp reported revenue of $37.22M, up 8.6% from a year earlier, and a net loss of $18.21M. Its operating margin was −34.7%, and operations used $9.15M in cash. In fiscal 2025, it reported revenue of $37.06M, up 4.1% from fiscal 2024, and a net loss of $8.20M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cytosorbents Corp does
In the company’s own words
CytoSorbents Corporation (Nasdaq: CTSO) develops and commercializes blood purification technologies based on porous polymer beads that remove harmful substances from blood and other bodily fluids. Its cartridges connect to standard hospital blood-pumping systems, including dialysis, continuous renal replacement therapy, ECMO and heart-lung machines. The lead product, CytoSorb, is used in critical care and cardiac surgery to remove inflammatory substances, toxins and certain blood-thinning drugs; it is approved in the European Union and distributed in more than 70 countries. More than 300,000 CytoSorb devices have been used cumulatively. Other products include ECOS-300CY for organ perfusion before transplantation, VetResQ for critical illness in animals, and the PuriFi hemoperfusion pump. DrugSorb-ATR, an investigational system for removing antithrombotic drugs during urgent cardiac surgery, is being developed for the U.S. and Canadian markets. Customers include hospitals and healthcare providers, distributors, and veterinary care providers. Its website is http://www.cytosorbents.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- PRINCETON, NJ
- Fiscal year end
- December
- CIK
- 1175151
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cytosorbents Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cytosorbents Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cytosorbents Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cytosorbents Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cytosorbents Corp's last four quarterly filings that the numbers alone won't show?”